After 100 years of use and billions of vaccinations, the world's deadliest infectious disease vaccine may soon be enhanced to meet the needs in 2025.
In a press release published on February 26, 2025, IAVI and Biofabri, a subsidiary of Zendal, announced that the first doses of tuberculosis MTBVAC vaccine candidate had been administered in the IMAGINE phase 2 clinical trial in Paarl, South Africa.
100 Year Old Tuberculosis Vaccine Getting an Upgrade
Obinutuzumab Efficacious for Renal Response in Lupus Nephritis
More patients receiving obinutuzumab plus standard therapy versus standard therapy alone had a complete renal response at week 76